Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Selexis S.A.. (7/7/16). "Press Release: Turgut Ilaclari A.S. and Selexis SA Sign Service and Commercial Agreements to Progress Development of Biosimilar Products". Geneva.

Organisations Organisation Selexis S.A.
  Group JSR Corporation (Group)
  Organisation 2 Turgut Ilaçlari A.S.
Products Product SURE CHO-M Cell line™
  Product 2 DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics)
Person Person Bocci, Marco (Selexis 201311– Director European Sales + Business Development before Quintiles)
     


Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and Turgut Ilaclari A.S., the leading biosimilar developer based in Turkey, announced today that they have entered into a service agreement that provides Turgut with access to Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the development of quality biosimilar products for the treatment of inflammatory diseases, certain cancers and two rare diseases.

“Our scientists, inspired by the innovation of our technology, are driven to provide high performance, cost-effective solutions to companies, such as Turgut, for therapeutic protein production,” said Marco Bocci, PhD, DPharm, Selexis vice president, licensing and business development. “We are pleased to report excellent progress on this project, recently completing two of the five cell lines. Partnerships are fundamental to our success, and we look forward to continuing our long-term relationship with Turgut.”

Selexis’s proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

The Selexis SURE CHO-M Cell Line is a proprietary high-performance mammalian cell line that is derived from CHO-K1 cells and used for the production of therapeutic recombinant proteins and monoclonal antibodies. The growth and production properties of the Selexis SURE CHO-M Cell Line are well defined, and the feed strategy has been optimized, allowing for faster and more efficient scale-up to bioreactors. Therapeutics that are generated using Selexis SURE CHO-M cells are in both clinical trials and marketed products.

In addition to the service agreement tied to the development of five Turgut biosimilar products, Turgut and Selexis have signed two commercial license agreements in conjunction with the first two Turgut products using the SURE CHO-M Cell Lines. Selexis is entitled to certain milestone payments and royalties if the product candidates reach defined clinical development stages and significant commercial sales levels.

Serdar Alpan, MD, PhD, Turgut Biotechnology Group Leader stated that, "Selexis’ industrial cell line technology is an important component of our biotechnology platform established for the development and production of high quality biosimilar monoclonal antibodies to improve human health in Turkey and globally.”


About Turgut Ilaclari A.S.

Turgut Group, with over 50 years’ experience, is one of the major entrepreneurs of Turkish pharmaceutical industry. The group has recently incorporated its pharmaceutical activities under the roof of Turgut Ilac, with a focus on biotechnology. With its global collaborations, established development platform and global standard GMP biotechnology manufacturing facility under construction, Turgut is the leading biotech company in Turkey with the vision to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States.


About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With nearly 90 clients worldwide and more than 70 drug products in clinical and commercial manufacturing utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.


FOR MORE INFORMATION

- Web www.selexis.com
- LinkedIn www.linkedin.com/company/selexis-sa
- Twitter www.twitter.com/SelexisSA
- Facebook www.facebook.com/SelexisSA

   
Record changed: 2019-04-26

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for JSR Corporation (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top